MicroRNAs in RPE Homeostasis and Disease

About the Research Project
Program
Award Type
Standard
Award Amount
$160,000
Active Dates
July 01, 2015 - June 30, 2017
Grant ID
M2015317
Goals
Age-related macular degeneration (AMD) is a major public health problem with devastating effects upon patients and composes a significant socio-economic burden worldwide. AMD affects 30% of individuals aged 70 years and older and its prevalence will rise as life expectancy increases due to changing demographics. In the past few years, significant progress has been made in the recognition of the genetic and environmental risk factors that predispose and elicit AMD. However, treatment options remain limited because the pathogenetic molecular mechanism of AMD is incompletely defined.
Summary
Recently, some small fragments of the human genome, termed microRNAs, have been identified and found to have a fundamental role in many biological processes, both in physiological and pathological conditions. The goal of this project is the study of the possible role of a microRNA, named miR-211, in RPE physiology, survival, and homeostasis both as causative agents and as therapeutic agents.
Grants
Related Grants
Macular Degeneration Research
Investigating AMD-Like Disease in Animal Models
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Brittany Carr, PhD
Investigating AMD-Like Disease in Animal Models
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Brittany Carr, PhD
Macular Degeneration Research
The Generation of Cone Photoreceptor Outer Segments
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Heike Kroeger, PhD
The Generation of Cone Photoreceptor Outer Segments
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Heike Kroeger, PhD
Macular Degeneration Research
Innovative Night Vision Tests for Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Maximilian Pfau, MD
Innovative Night Vision Tests for Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Maximilian Pfau, MD